Age | ANAa | SSc-associated antibodiesb | SSc-subtype | mRSS | %pVCc | %pDLCOd | Disease duration (months)e | Sex | BAL cellularity, distribution (%) | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lymphocytes | Neutrophils | Eosinophils | Macrophages | Other | ||||||||||
Pat 1 | 28 | ANA positive. Nucleolar | Anti-PM/Scl | lcSSc | 2 | 66 | 61 | 11 | F | 0 | 0 | 0 | 96 | 4 |
Pat 2 | 55 | ANA positive. Centromere | Anti-Ro52 ACA | lcSSc | 2 | 88 | 76 | 108 | F | 9 | 0 | 0 | 75 | 16 |
Pat 3 | 59 | ANA positive. Speckled | Anti-Ro52 Anti-Ro60 Anti-La/SSB Anti-U1RNP | lcSSc | 4 | 101 | 80 | N/A | M | 8 | 42 | 2 | 29 | 19 |
Pat 4 | 40 | ANA positive. Nucleolar | Anti-PM/Scl Anti-U1RNP | dcSSc | 6 | 80 | 42 | 24 | M | 13 | 10 | 5 | 57 | 15 |
Pat 5 | 55 | ANA positive. Speckled | Anti-Scl-70 | dcSSc | 19 | 56 | 32 | 2 | M | 9 | 4 | 5 | 74 | 8 |
Pat 6 | 68 | ANA positive. Speckled and homogenous | - | lcSSc | 5 | 73 | 57 | 72 | F | 8 | 4 | 1 | 78 | 9 |
Pat 7 | 68 | ANA positive. Speckled | Anti-Scl-70 | lcSSc | 9 | 57 | 45 | 50 | F | 12 | 20 | 0 | 54 | 14 |
Pat 8 | 68 | ANA positive. Nucleolar | - | lcSSc | 3 | 85* | 88* | 15 | F | 26 | 23 | 4 | 39 | 8 |
Pat 9 | 58 | ANA positive. Nucleolar | Anti-Ro52 Anti-PM/Scl | dcSSc | 34 | 62 | 28 | 11 | M | 7 | 6 | 7 | 57 | 23 |
Pat 10 | 56 | ANA positive. Nucleolar | Anti-PM/Scl | dcSSc | 20 | 70 | 81 | 40 | F | 9 | 28 | 2 | 35 | 26 |
Pat 11 | 67 | ANA-negative | - | dcSSc | 10 | 56 | 39 | 8 | F | 16 | 6 | 5 | 70 | 3 |
Pat 12 | 50 | ANA positive. Homogenous | Anti-Ro52 | dcSSc | 15 | 93 | 62 | 12 | F | 5 | 1 | 1 | 93 | 0 |
Pat 13 | 70 | ANA positive, pattern could not be defined | ACA | lcSSc | 2 | 122 | 69 | 6 | F | 8 | 5 | 1 | 86 | 0 |
Pat 14 | 57 | ANA negative | Anti-Ro60 | dcSSc | 19 | 95 | 62 | 36 | M | 6 | 5 | 4 | 84 | 1 |
Pat 15 | 46 | ANA negative | Anti-Ro52 | dcSSc | 9 | 63 | 53 | 10 | M | 7 | 0 | 4 | 84 | 5 |